The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Day One Biopharmaceuticals Inc. shares valued at $2,900,425 were sold by Grant Julie Papanek on Sep 20. At $19.51 per share, Grant Julie Papanek sold 148,670 shares. The insider’s holdings dropped to 9,077,904 shares worth approximately $166.13 million following the completion of this transaction.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Also, Canaan XI L.P. sold 148,670 shares, netting a total of over 2,900,425 in proceeds. Following the sale of shares at $19.51 each, the insider now holds 9,077,904 shares.
Before that, Canaan XI L.P. had sold 76,725 shares from its account. In a trade valued at $1,578,233, the 10% Owner traded Day One Biopharmaceuticals Inc. shares for $20.57 each. Upon closing the transaction, the insider’s holdings decreased to 76,725 shares, worth approximately $168.85 million.
Analyzing DAWN’s Price Performance
On Wednesday, Day One Biopharmaceuticals Inc. [NASDAQ: DAWN] plunged -7.01% to $18.30. The stock’s lowest price that day was $18.26, but it reached a high of $19.64 in the same session. During the last five days, there has been a drop of approximately -21.53%. Over the course of the year, Day One Biopharmaceuticals Inc. shares have jumped approximately 8.61%. Shares of the company reached a 52-week high of $28.35 on 08/12/22 and a 52-week low of $5.44 on 05/27/22. A 50-day SMA is recorded $21.87, while a 200-day SMA reached $15.06. Nevertheless, trading volume fell to 1.38 million shares from 1.12 million shares the previous day.
Support And Resistance Levels for Day One Biopharmaceuticals Inc. (DAWN)
According to the 24-hour chart, there is a support level at 17.83, which, if violated, would cause prices to drop to 17.35. In the upper region, resistance lies at 19.21. The next price resistance is at 20.11. RSI (Relative Strength Index) is 29.50 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -3.47, which suggests the price will decrease in the coming days. Percent R is at 99.53%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is Day One Biopharmaceuticals Inc. subject to short interest?
Stocks of Day One Biopharmaceuticals Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 0.63 million shares to 7.81 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 7.18 million shares. A jump of 8.07% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.8 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.8.
Which companies own the most shares of Day One Biopharmaceuticals Inc. (DAWN)?
According to RA Capital Management LP filings, the company currently owns 7,040,622 shares, which is about 9.58% of the total DAWN shares outstanding. The investor’s shares have appreciated by 980,532 from its previous 13-F filing of 6060090.0 shares. With the completion of the buy transaction, Fidelity Management & Research Co’s stake is now worth $159,502,761. Deerfield Management Co. LP acquire a 68.33% interest valued at $82.5 million while Adage Capital Management LP purchased a 2,570,976 stake. A total of -352,849 shares of Day One Biopharmaceuticals Inc. were bought by The Vanguard Group, Inc. during the quarter, and 915,484 were bought by Franklin Advisers, Inc. In its current portfolio, T. Rowe Price Associates, Inc. holds 2,041,344 shares valued at $47.95 million.
In terms of Day One Biopharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $36.75 in the next 12 months, up nearly 90.55% from the previous closing price of $19.68. Analysts anticipate Day One Biopharmaceuticals Inc. stock to reach $40.00 by 2022, with the lowest price target being $32.00. In spite of this, 5 analysts ranked Day One Biopharmaceuticals Inc. stock as a Buy at the end of 2022.